期刊文献+

miRNA-449a在人肺癌及癌旁组织中的差异表达 被引量:3

Different expression of miRNA-449a in lung cancer and precancerous tissue
下载PDF
导出
摘要 目的探讨miRNA-449a在人肺癌及癌旁组织中的表达差异及其临床意义。方法右江民族医学院附属医院2011-01-01—2013-06-30收治的肺癌患者58例,对照组为癌旁正常组织,病例组为鳞癌组织和腺癌组织,并根据miRNA-449a序列结构设计合成miRNA-449a模拟物,设10和20 mg/m L两个不同浓度,以0 mg/m L为阴性对照,用real-time PCR检测肺癌及其对应癌旁组织中miRNA-449a的表达;化学发光技术检测细胞内荧光素酶基因表达;四甲基偶氮唑蓝法检测细胞活性。结果鳞癌组和腺癌组的miRNA-449a的表达量为1.48±1.63和1.52±1.54,均显著低于癌旁正常对照组的2.74±1.55(P<0.01),且与瘤体大小有关(P<0.05)。10和20 mg/m L组细胞内的平均荧光强度为2 115±168和1 352±159,均显著低于阴性对照组的4 975±115(P<0.01),且抑制作用随浓度增加呈递增趋势。结论 miRNA-449a在肺癌组织中呈低表达,可下调细胞内荧光蛋白表达和诱导细胞凋亡。 Objective To investigate the expression and biological function of miRNA-449 a in lung cancer.Methods A case-control study was conducted in 58 patients diagnosed with lung cancer( carcinoma and adenocarcinoma) and normal tissue closely adjacent to tumor. MiRNA-449 a simulation was designed and synthesized,was dissolved into two different concentrations as 10 and 20 mg / m L. The expression of miRNA-449 a in lung cancer tissues and matched normal tissues were detected by Real time PCR. The expression of luciferase gene was detected by chemiluminescence technique. MiRNA-449 a mimics on cell apoptosis was evaluated by MTT assay.Results The mean tissues expression levels of miRNA-449 a in squamous carcinoma group and adenocarcinoma group were 1. 48 ± 1. 63 and 1. 52 ± 1. 54 respectively,and were significantly lower than in control group( 2. 74 ±1. 55)( P < 0. 01). The average intensity of fluorescent protein in 10 mg / m L group and 20 mg / m L group were2 115 ± 168 and 1 352 ± 159 respectively,and were significantly lower than that in control group( 4 975 ± 115)( P < 0. 01). Conclusions MiRNA-449 a was down-regulated expression in lung cancer and induced apoptosis.
出处 《基础医学与临床》 CSCD 2015年第1期44-47,共4页 Basic and Clinical Medicine
基金 广西自然科学基金(2011GXNSFA0198215)
关键词 肺肿瘤 miRNA-449a 肿瘤标志 聚合酶链反应 荧光定量 lung neoplasms miRNA-449a tumor biomarker polymerase chain reaction fluorogenic quantitative
  • 相关文献

参考文献11

  • 1Wan-qing C hen,Rong-shou Zheng,Si-wei Zhang,Ni Li,Ping Zhao,Guang-lin Li,Liang-you Wu,Jie He.Report of Incidence and Mortality in China Cancer Registries,2008[J].Chinese Journal of Cancer Research,2012,24(3):171-180. 被引量:48
  • 2Miep A. van der Drift,Henrike E. Karim-Kos,Sabine Siesling,Harry J. M. Groen,Michel W. J. M. Wouters,Jan-Willem Coebergh,Esther de Vries,Maryska L. G. Janssen-Heijnen.Progress in Standard of Care Therapy and Modest Survival Benefits in the Treatment of Non-small Cell Lung Cancer Patients in the Netherlands in the Last 20 Years[J]. Journal of Thoracic Oncology . 2012 (2)
  • 3WenruiDuan,LiGao,XinWu,LiWang,Serge P.Nana‐Sinkam,Gregory A.Otterson,Miguel A.Villalona‐Calero.MicroRNA‐34a is an important component of PRIMA‐1‐induced apoptotic network in human lung cancer cells[J]. Int. J. Cancer . 2010 (2)
  • 4William C.S. Cho,Andrew S.C. Chow,Joseph S.K. Au.Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation[J]. European Journal of Cancer . 2009 (12)
  • 5Amaia Lujambio,Scott W. Lowe.The microcosmos of cancer. Nature . 2012
  • 6Lena J Chin Frank J Slack.A truth serum for cancer -- microRNAs have major potential as cancer biomarkers[J].Cell Research,2008,18(10):983-984. 被引量:39
  • 7Guido Carillio,Agnese Montanino,Raffaele Costanzo.Cetuximab in non-small-cell lung cancer. EXPERT REVIEW OF ANTICANCER THERAPY . 2012
  • 8Guo Huili,Ingolia Nicholas T,Weissman Jonathan S,Bartel David P.Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature . 2010
  • 9Xiaojing Yang,Min Feng,Xia Jiang,Zhenlong Wu,Zhimei Li,Meiyee Aau,Qiang.miR-449a and miR-449b are direct transcriptional targets of E2F1 and negatively regulate pRb–E2F1 activity through a feedback loop by targeting CDK6 and CDC25A. Genes and Development . 2009
  • 10Incoronato Mariarosaria,Garofalo Michela,Urso Loredana,Romano Giulia,Quintavalle Cristina,Zanca Ciro,Iaboni Margherita,Nuovo Gerald,Croce Carlo Maria,Condorelli Gerolama.miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Research . 2010

二级参考文献11

  • 1Bray F, Parkin OM. Evaluation of data quality in the cancer registry: principles and methods. Part I: comparability, validity and timeliness. Eur J Cancer 2009; 45:747-55.
  • 2National Central Cancer Registry. Guideline for cancer registration in China (in Chinese). Beijing: Peking Union Medical College Publication House; 2004.
  • 3Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Vol. IX. IARC Scientific Publications No. 160. Lyon: IARC; 2008.
  • 4Parkin OM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon: IARC; 1994.
  • 5Felay J, Burkhard C, Whelan SO, et al. Check and conversion programs for cancer registries. IARC Technical Report No. 42. Lyon: IARC; 2005.
  • 6Chen JG. The evaluation on data quality for cancer register. Chin Cancer (in Chinese) 1999; 8:100-4.
  • 7Felay J. The IARC crgTools program. Lyon: IARC; 2006. http://www.iacr.com.fr/iarccrgtools.htm.
  • 8Ministry of Health. The third national survey for cause of death (in Chinese). Beijing: Peking Union Medical College Publication House; 2008.
  • 9Zhang SW, Lei ZL, LI GL, et al. Incidence and mortality from China cancer registries in 2005. Zhong Guo Zhong Liu (in Chinese) 2009; 18:973-9.
  • 10Zhao P, Chen WQ. Annual report of China cancer 2008 (in Chinese). Beijing: Military Medical Sciences Press; 2009.

共引文献85

同被引文献18

  • 1蔡伟,叶青,唐亮,余伯成,郑民华.虫草素对结肠癌细胞体外增殖、迁移能力的影响及其诱导细胞凋亡的作用[J].中华临床医师杂志(电子版),2011,5(14):4048-4054. 被引量:10
  • 2Nieder C.Prognostic benefit of postoperative radiotherapy with adjuvant chemotherapy for stage IIIA/N2,pathologic nonsmall-cell lung cancer[J].StrahlentherOnkol,2015,191(6):539-540.
  • 3Chen N,Ren M,Li R,et al.Bevacizumab promotes venous thromboembolism through the induction of PAI-1in a mouse xenograft model of human lung carcinoma[J].Mol Cancer,2015,14(1):140.
  • 4Crvenkova S,Pesevska M.Important prognostic factors for the long-term survival in non-small cell lung cancer patients treated with combination of chemotherapy and conformal radiotherapy[J].J BUON,2015,20(3):775-781.
  • 5Aramwit P,Porasuphatana S,Srichana T,Nakpheng T.Toxicity evaluation of cordycepin and its delivery system for sustained in vitro anti-lung cancer activity[J].Nanoscale Res Lett,2015,27(10):152.
  • 6Syrios J,Nintos G,Georgoulias V.Nintedanib in combination with docetaxel for second-line treatment of advanced non-smallcell lung cancer[J].Expert Rev Anticancer Ther,2015,15(8):875-884.
  • 7Kim H,Naura AS,Errami Y,et al.Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP[J].Mol Med,17(9-10):893-900.
  • 8Zhu W,He J,Chen D,et al.Expression of miR-29c,miR-93,and miR-429as potential biomarkers for detection of early stage non-small lung cancer[J].PLoS One,2014,9(2):e87780.
  • 9Zarogoulidis P,Petanidis S,Kioseoglou E,Domvri K,Anestakis D,Zarogoulidis K.MiR-205and miR-218expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1and Survivin in lung cancer cells[J].Cell Signal,2015,27(8):1576-1588.
  • 10Kennedy RK,Veena V,Naik PR,et al.Phenazine-1-carboxamide(PCN)from Pseudomonas sp.strain PUP6selectively induced apoptosis in lung(A549)and breast(MDA MB-231)cancer cells by inhibition of antiapoptotic Bcl-2family proteins[J].Apoptosis,2015,20(6):858-868.

引证文献3

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部